Compounded tirzepatide with NAD+ and L-carnitine is a multi-ingredient formulation combining a dual GIP/GLP-1 receptor agonist with nicotinamide adenine dinucleotide and levocarnitine in a single preparation. Compounding pharmacies prepare it when a prescriber documents a patient-specific clinical need that an FDA-approved product cannot meet.
Among GLP-1 formulations ordered through ScriptLinkRx, this two-additive combination is the #8 most-prescribed compounded product, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. It also carries the highest regulatory scrutiny of any GLP-1 preparation covered here: each added ingredient must stand on its own documented clinical rationale, and multi-ingredient combinations face more regulatory questions than any single-agent or single-additive GLP-1 formulation.
What Tirzepatide, NAD+, and L-Carnitine Are
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Through those two incretin pathways it influences insulin secretion, gastric emptying, and appetite signaling. The molecule is the active ingredient in FDA-approved branded products indicated for type 2 diabetes and for chronic weight management in adults meeting labeled criteria.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, involved in redox reactions and cellular energy metabolism. It is not an FDA-approved drug. Longevity, wellness, and metabolic practices order it on the basis of cellular-energy and metabolic rationales.
L-carnitine (levocarnitine) is a compound involved in the transport of long-chain fatty acids into mitochondria for beta-oxidation. FDA-approved levocarnitine products exist for specific indications such as primary and secondary carnitine deficiency; use as a general metabolic additive in a compounded GLP-1 preparation falls outside those approved indications.
Combining all three in one preparation means a single injection delivers an incretin agonist alongside two metabolic cofactors. The regulatory implication is straightforward: each of the three components carries its own status and its own justification burden.
How Providers Use It in Practice
Clinics that order compounded tirzepatide with NAD+ and L-carnitine are typically in the weight-management and metabolic space, including medical weight-loss practices, longevity and wellness clinics, and some primary-care and endocrinology-adjacent settings. The combination is generally positioned within a broader metabolic or body-composition program rather than as a standalone therapy.
The stated rationale providers usually offer is convenience and adherence: consolidating an incretin agonist and metabolic cofactors into one preparation reduces the number of separate injections a patient manages. It is important to describe this neutrally. The additives have not been studied in combination with tirzepatide in the large controlled trials that supported the branded product's approval, and combining them does not confer the efficacy or safety profile of any FDA-approved drug. Providers who prescribe the combination take on responsibility for the clinical judgment behind each component.
Because this formulation stacks two additives, it tends to draw more scrutiny than single-agent or single-additive GLP-1 variants. A prescriber choosing it should be prepared to articulate, per patient, why NAD+ is indicated and, separately, why L-carnitine is indicated, in addition to the tirzepatide rationale itself.
Forms and Combinations Available Through Compounding
Compounded tirzepatide combinations are most commonly prepared as sterile injectables for subcutaneous administration. The rationale for compounding a multi-ingredient product is patient-specific customization: a licensed prescriber determines that an individual patient requires a formulation the manufactured product does not provide, and a licensed pharmacy prepares it to that specification.
Related formulations in this category include:
- Single-agent compounded tirzepatide.
- Tirzepatide with a single vitamin additive, such as compounded tirzepatide with B6.
- Tirzepatide with L-carnitine alone, covered in compounded tirzepatide with L-carnitine.
- Standalone compounded NAD+, ordered by longevity and wellness practices.
This article intentionally omits strengths, dosing, and titration. Those are individualized clinical decisions made by the prescriber and the dispensing pharmacist, not content for an educational overview.
Regulatory Status and Provider Considerations
The regulatory picture for compounded tirzepatide changed materially over the past two years, and the two-additive combination sits at the sharpest end of it.
The shortage is resolved. FDA determined the tirzepatide shortage resolved and re-affirmed that determination on December 19, 2024. The agency set transition periods during which it did not intend to take enforcement action against compounders producing copies of the branded product: 503A pharmacies through February 18, 2025, and 503B outsourcing facilities through March 19, 2025 (as of July 2026). With the shortage over, tirzepatide is no longer eligible for compounding on shortage grounds.
The "essentially a copy" framework now governs. Outside a shortage, a 503A pharmacy compounding a drug that is essentially a copy of a commercially available FDA-approved product must document a patient-specific clinical difference — a change that produces a significant difference for that individual patient, as determined by the prescriber. A combination product may be argued to be more than a copy because it contains additional active ingredients, but that argument does not remove the underlying obligation to justify the formulation; FDA has questioned whether blanket additive rationales meet the individualized-need standard.
Additives require individualized justification — twice here. FDA has publicly questioned the clinical rationale for adding ingredients like B vitamins and levocarnitine to GLP-1 compounds, noting these combinations were not evaluated in the trials supporting the branded drugs. The responsibility to justify each additive on a patient-specific basis rests with the prescriber. Because this preparation contains two additives, that burden applies independently to NAD+ and to L-carnitine. This is the plain reason multi-ingredient GLP-1 combinations tend to face more regulatory questions than single-agent or single-additive formulations.
Proposed exclusion from the 503B bulks list. On May 1, 2026, FDA published a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these substances from bulk. The comment period was extended to July 30, 2026 (as of July 2026). If finalized, it would further constrain 503B compounding of tirzepatide.
Nothing here should be read to suggest compounded tirzepatide combinations are FDA-approved or equivalent to any branded product. They are not. Compounded drugs are not FDA-approved, are not reviewed by FDA for safety and efficacy before marketing, and do not carry the manufactured product's approval. Clinics order compounded medications through platforms like ScriptLinkRx that connect them with licensed compounding pharmacies; the compliance judgment for each prescription remains with the prescriber and pharmacist.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Because this is a sterile, multi-ingredient injectable, sourcing diligence matters more, not less. Questions worth asking any pharmacy before ordering:
- API source and Certificates of Analysis. Request the source of the tirzepatide active pharmaceutical ingredient and CoAs for each component, including NAD+ and levocarnitine.
- USP compliance. Confirm adherence to USP <795> (non-sterile compounding), <797> (sterile compounding), and <800> (hazardous drugs) as applicable to the preparation.
- Potency and sterility testing. Ask about potency assays, sterility testing, and endotoxin testing on the finished multi-ingredient product — not just the individual inputs.
- Beyond-use dating. Understand the assigned beyond-use date and the stability data supporting it for the specific combination, since combining ingredients can affect stability.
- State licensure and facility type. Verify the pharmacy's licensure in the states where it dispenses and whether it operates as a 503A pharmacy or 503B outsourcing facility, since the applicable rules differ.
- Compatibility rationale. For a two-additive product, ask what data or references support physical and chemical compatibility of tirzepatide with both NAD+ and L-carnitine in a single preparation.
Frequently Asked Questions
Is compounded tirzepatide with NAD+ and L-carnitine FDA-approved?
No. No compounded drug is FDA-approved. The branded tirzepatide products are FDA-approved for their labeled indications, but a compounded multi-ingredient preparation is not reviewed or approved by FDA and is not equivalent to any manufactured product.
Why does this combination draw more regulatory scrutiny than single-additive tirzepatide?
Because it stacks two additives. Each added ingredient — NAD+ and L-carnitine — needs its own documented, patient-specific clinical rationale, on top of the justification for the tirzepatide itself. FDA has questioned blanket additive rationales, so more components mean more questions.
Can pharmacies still compound tirzepatide now that the shortage is resolved?
The shortage-based pathway closed after the 2024 resolution and the early-2025 transition periods. Outside a shortage, compounding is governed by the essentially-a-copy framework, which for 503A pharmacies requires a documented patient-specific clinical difference. A May 2026 FDA proposal would further limit 503B bulk compounding of tirzepatide.
Who is responsible for justifying the additives?
The prescriber. The individualized clinical need for each ingredient is the prescriber's documented determination, and the dispensing pharmacist shares responsibility for compounding within applicable rules.
Related Reading
- See where tirzepatide combinations rank among the most-prescribed compounded medications
- Compounded tirzepatide with B6
- Compounded tirzepatide with L-carnitine
- Compounded NAD+
Sources
- FDA: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- FDA: Declaratory Order — Resolution of Shortages of Tirzepatide Injection
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B — Extension of Comment Period (June 26, 2026)
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
